{
    "nctId": "NCT04650581",
    "briefTitle": "Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor",
    "officialTitle": "Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 250,
    "primaryOutcomeMeasure": "Progression-free survival (PFS) using RECIST 1.1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically and/or cytologically confirmed ER positive, HER-2 negative breast cancer\n* Female patients must be post-menopausal; female patients who are pre-menopausal must have ovarian suppression using LHRH agonist while on study\n* Clinical and/or radiographic progression during treatment with or within 28 days after discontinuation of first line of treatment with a CDK 4/6 inhibitor and an aromatase inhibitor (AI) for advanced/metastatic disease\n* Evidence of clinically and/or radiologically documented disease\n* \u2265 18 years of age\n* ECOG performance status of 0 or 1\n* No concurrent anti-cancer therapy and must satisfy the following criteria for previous therapy\n\n  * Must not have received more than one prior line of treatment with a CDK 4/6 inhibitor and an AI in the advanced disease setting.\n  * Treatment with CDK 4/6 inhibitor and AI must have been the most recent treatment prior to registration for this study\n* Adequate hematology and organ function, in the absence of growth factors\n\n  * Absolute neutrophils \\> 1.5 x 10\\^9/L\n  * Platelets \u2265 100 x 10\\^9/L\n  * Hemoglobin \\> 90 g/L\n  * Total Bilirubin \u2264 1.5 x ULN (upper limit of normal) or \u2264 3 x ULN if confirmed Gilbert's Syndrome\n  * ALT and AST \u2264 2.5 x ULN (or \u2264 5.0 x ULN if liver or bone metastasis)\n  * Alkaline phosphatase \u2264 2.0 x ULN (or \u2264 5.0 x ULN if liver metastases, \u2264 7.0 x ULN if bone metastasis)\n  * Fasting glucose \u2264 8.3 mmol/L\n  * HbA1c \u2264 7.5%\n  * Serum albumin \u2265 30 g/L\n  * INR \u2264 1.2\n  * Serum Creatinine or Creatinine clearance \u2264 1.5 x ULN or \u2265 50 mL/min; measured directly by 24-hour urine sampling or as calculated by Crockcroft and Gault equation\n\nExclusion Criteria:\n\n* Untreated or symptomatic CNS metastases, radiation treatment for CNS metastases within 28 days\n* Active inflammatory bowel disease, bowel inflammation, inability to swallow oral medication or GI condition that alters oral absorption\n* Prior treatment with fulvestrant, selective estrogen receptor degraders (SERDs) or known inhibitors of the PI3K pathway including PI3K inhibitors, AKT inhibitors, or mTOR inhibitors\n* Mean QT interval corrected for heart rate (QTc) \u2265 480 msec by ECG or history of familial long QT syndrome\n* Active or uncontrolled infections or serious illnesses or medical conditions\n* Clinically significant liver diseases\n* History of lung disease or history of opportunistic infections\n* Type 1 or Type 2 diabetes mellitus requiring insulin\n* Grade \u2265 2 uncontrolled hypercholesterolemia or hypertriglyceridemia\n* Known abnormalities in coagulation\n* History of hypersensitivity to the study drugs or components\n* Pregnant or lactating women",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}